for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead to buy 49.9% stake in cancer drug developer Pionyr for $275 mln

June 23 (Reuters) - Gilead Sciences Inc said on Tuesday it would buy a 49.9% stake in privately held cancer immunotherapies developer Pionyr Immunotherapeutics Inc for $275 million.

The drugmaker said it has also secured the right to acquire remainder of Pionyr for a $315 million option exercise fee. (Reporting by Manojna Maddipatla in Bengaluru)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up